Thursday Apr 10
Pre-Market Scans on Top Gainers -- Research on Athlon Energy,...
The session saw a positive impact from Information Technology, Health Care and Materials sectors along with a drag from Utilities and Telecommunication Services sectors.
Trending on the Topix Network
Thursday Apr 10
Stocks to Watch Thursday: VIVUS, Inc., Zillow Inc, and ImmunoGen, Inc.
Interestingly, short-term call open interest has almost doubled since March 24, while put open interest climbed less than 1%.
Tue Apr 08, 2014
ImmunoGen, Inc. Announces First Clinical Findings with Refined Dosing Strategy for IMGN853
The data were presented at the American Association for Cancer Research Annual Meeting in San Diego, CA.
Mon Apr 07, 2014
Immunogen Rating Increased to Outperform at Zacks
The firm currently has a $15.90 target price on the stock. Zacks 's price objective suggests a potential upside of 19.64% from the company's previous close.
Tue Apr 01, 2014
SAGE Therapeutics Appoints Howard H. Pien to the Companya s Board of Directors
"Howard is a seasoned industry leader with deep biopharmaceutical expertise, especially in guiding companies as they expand and evolve from research and development to clinical stage," said Jeff Jonas, M.D., chief executive officer of SAGE Therapeutics.
Fri Mar 28, 2014
Friday's ETF Movers: GXC, FBT
Components of that ETF showing particular strength include shares of , up about 7.8% on the day.
Thu Mar 20, 2014
ImmunoGen Schedules Presentations by Company Scientists at Upcoming AACR Annual Meeting
"They also include highly encouraging preclinical findings with both our IMGN289 and IMGN853 compounds, as well as data on some of the more recent additions to our ADC technology portfolio."
Tue Mar 18, 2014
Immunogen CEO Sells $246,000 in Stock
Immunogen CEO Daniel M. Junius sold 15,000 shares of the stock on the open market in a transaction that occurred on Monday, March 17th.
Mon Mar 17, 2014
ImmunoGen, Inc. Announces Presentations by Company Scientists at Upcoming AACR Annual Meeting
'The presentations scheduled include the pharmacokinetics modeling work which informed our decision to dose IMGN853 based on adjusted ideal body weight and to assess it dosed weekly,' commented , Ph.D., Executive Vice President and Chief Scientific Officer.